Midazolam prevents motor neuronal death from oxidative stress attack mediated by JNK-ERK pathway
| Autor: | Hong-Lei Tao, Cong-bin Peng, Cheng Zhou, Guo-zheng Li, Dong-dong Wang |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
MAPK/ERK pathway Cancer Research Programmed cell death genetic structures MAP Kinase Signaling System Midazolam Pharmacology medicine.disease_cause Cell Line 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine mental disorders medicine Humans Hypnotics and Sedatives heterocyclic compounds Phenylarsine oxide Motor Neuron Disease chemistry.chemical_classification Motor Neurons Reactive oxygen species Cell Death Cell Biology Motor neuron Oxidative Stress 030104 developmental biology medicine.anatomical_structure chemistry Apoptosis psychological phenomena and processes 030217 neurology & neurosurgery Oxidative stress medicine.drug |
| Zdroj: | Human cell. 31(1) |
| ISSN: | 1749-0774 |
| Popis: | Midazolam is a sedative used by patients with mechanical ventilation. However, the potential clinical value is not fully explored. In this report, we made use of a neuroblastoma-spinal cord hybrid motor neuron-like cell line NSC34, and elucidated the potential role of Midazolam on these cells under the insult of oxidative stress. We found the protective effect of Midazolam on motor neurons against cytotoxicity induced by the combination of oligomycin A and rotenone (O/R) or phenylarsine oxide. The characteristics of apoptosis, such as the ratio of TUNEL+ cells or the expression level of cleaved Caspase-3, was decreased by 22 or 45% in the presence of Midazolam. Furthermore, this effect was correlated with the JNK-ERK signaling pathway. Either phosphorylation of ERK or JNK was positively or negatively modulated with the treatment of Midazolam in NSC34 cells attacked by reactive oxygen species. Meanwhile, inhibition or activation of the JNK-ERK pathway regulated the protective effect of Midazolam on NSC34 cells with oxidative stress insult. Collectively, this study elucidated a previously unidentified clinical effect of Midazolam, and put forward the great promise that Midazolam may be considered as a potential candidate to the treatment of motor neuron disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink